Zhaohui Su: What ESMO 2025 Revealed About AI

Zhaohui Su, VP of Biostatistics at Ontada, shared a post on LinkedIn:

“At the European Society for Medical Oncology (ESMO) 2025 in Berlin, attended by approximately 37,000 clinicians, researchers, and others, AI emerged as a central theme. It reinforced AI’s potential in oncology, showcasing innovations that demonstrate how AI is transforming evidence generation, from foundation models trained on EHR data to AI-driven trial matching and decentralized trial designs.

Key highlights included:

•  EBAI Framework: New guidance for validating AI-based biomarkers, ensuring clinical relevance and regulatory alignment.
•  Digital Trials: AI-enabled tools enhancing retention, diversity, and data quality.
•  TrialMatchAI: An open-source platform optimizing eligibility and accelerating enrollment.
•  Synthetic Data & Federated Learning: Promising methods for privacy-preserving collaboration, with a focus on validation.

AI is no longer experimental; it is now integral. Future success will depend on transparency, rigorous validation, and collaboration to ensure AI enhances the integrity and impact of oncology research.

For more details, visit the link.”

More posts featuring Zhaohui Su.